MétaCan
Menu
← Back to cohort
Record W2913386403 · doi:10.1093/ecco-jcc/jjy222.755

P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis

2019· article· en· W2913386403 on OpenAlexaff
Parambir S. Dulai, Siddharth Singh, Niels Vande Casteele, Joseph Meserve, Adam C. Winters, Shreya Chablaney, Satimai Aniwan, Preeti Shashi, Gursimran Kochhar, Aaron Weiss, Jenna L. Koliani‐Pace, Youran Gao, Brigid S. Boland, John T. Chang, David M. Faleck, Robert Hirten, Ryan C. Ungaro, Dana J. Lukin, Keith Sultan, David Hudesman, Sam S. Chang, Matthew Bohm, Sashidhar Varma, Monika Fischer, Eugenia Shmidt, Arun Swaminath, Nitin Gupta, Maria Rosario, Vipul Jairath, Leonardo Guizzetti, Brian G. Feagan, Corey A. Siegel, Bo Shen, Sunanda V. Kane, Edward V. Loftus, William J. Sandborn, B E Sands, J F Colombel, Karen Lasch, Chang Cao

Bibliographic record

VenueJournal of Crohn s and Colitis · 2019
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsRobarts Clinical TrialsWestern University
Fundersnot available
KeywordsVedolizumabUlcerative colitisLogistic regressionMedicineInternal medicineConfidence intervalMathematicsStatisticsDisease

Abstract

fetched live from OpenAlex

We created and validated a clinical decision support tool (CDST) for vedolizumab (VDZ) therapy in active ulcerative colitis (UC). To identify factors associated with corticosteroid-free remission (CSFREM; full Mayo score ≤2, no sub-score >1), logistic regression analyses were run on data from the GEMINI 1 VDZ trial for UC (derivation set; n = 620) and used to develop a CDST. Correlations between VDZ exposure, onset of action, and efficacy across predicted-probability groups were explored, and the CDST was externally validated in an observational cohort of VDZ-treated UC patients (validation set; n = 199). Factors independently associated with CSFREM were absence of previous tumour necrosis factor antagonist exposure (+3 points), disease duration ≥2 years (+3 points), baseline endoscopic activity (moderate vs. severe) (+2 points), and baseline albumin concentration (+0.65 points per g/l). Patients were stratified into low (≤26 points), intermediate (>26 to ≤32 points), or high (>32 points) probability of response groups. The higher probability group more rapidly achieved symptom activity reductions and attained higher rates of CSFREM (p < 0.001). In the validation set, a 26-point cut-off value showed high sensitivity (93%) for identifying non-responders. A statistically significant linear relationship was observed between VDZ exposure, probability groups, and efficacy in the derivation set (p < 0.001). In the validation set, only the low–intermediate probability group benefited from VDZ interval shortening for lack of response (p = 0.02). We developed and externally validated a CDST with good discriminative performance for predicting CSFREM with VDZ in UC patients. Pending further validation, this tool could be a helpful aid in identifying patients who would benefit from VDZ interval shortening due to insufficient response. (GEMINI 1: NCT00783718).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.010
metaresearch head score (Gemma)0.030
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Methods · Consensus signal: none
Teacher disagreement score0.010
Threshold uncertainty score0.053

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0100.030
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0000.000
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.274
Teacher spread0.262 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and Colitis→Same topicInflammatory Bowel Disease→French-language works237,207→